kr177.00
3.15% today
Stockholm, Dec 04, 02:02 pm CET
ISIN
SE0004840718
Symbol
XVIVO

Xvivo Perfusion Stock price

kr171.60
-10.90 5.97% 1M
-138.60 44.68% 6M
-317.40 64.91% YTD
-305.90 64.06% 1Y
-21.80 11.27% 3Y
-157.90 47.92% 5Y
+150.80 725.00% 10Y
+151.70 762.31% 20Y
Stockholm, Closing price Wed, Dec 03 2025
-0.80 0.46%
ISIN
SE0004840718
Symbol
XVIVO

Key metrics

Basic
Market capitalization
kr5.8b
Enterprise Value
kr5.7b
Net debt
positive
Cash
kr279.9m
Shares outstanding
31.5m
Valuation (TTM | estimate)
P/E
182.6 | 72.4
P/S
7.1 | 7.1
EV/Sales
7.0 | 6.9
EV/FCF
74.2
P/B
2.8
Financial Health
Equity Ratio
89.8%
Return on Equity
8.0%
ROCE
3.0%
ROIC
-
Debt/Equity
0.1
Financials (TTM | estimate)
Revenue
kr813.6m | kr824.0m
EBITDA
kr115.1m | kr188.0m
EBIT
kr67.0m | kr82.4m
Net Income
kr29.9m | kr74.6m
Free Cash Flow
kr76.2m
Growth (TTM | estimate)
Revenue
8.4% | 0.2%
EBITDA
-12.5% | 21.4%
EBIT
18.1% | -7.8%
Net Income
-85.4% | -56.7%
Free Cash Flow
13.2%
Margin (TTM | estimate)
Gross
75.0%
EBITDA
14.2% | 22.8%
EBIT
8.2%
Net
3.7% | 9.1%
Free Cash Flow
9.4%
More
EPS
kr0.9
FCF per Share
kr2.4
Short interest
-
Employees
193
Rev per Employee
kr4.3m
Show more

Is Xvivo Perfusion a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,088 stocks worldwide.

Xvivo Perfusion Stock Analysis

Unlock Scores for Free

Analyst Opinions

13 Analysts have issued a Xvivo Perfusion forecast:

11x Buy
85%
2x Hold
15%

Analyst Opinions

13 Analysts have issued a Xvivo Perfusion forecast:

Buy
85%
Hold
15%

Financial data from Xvivo Perfusion

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
814 814
8% 8%
100%
- Direct Costs 203 203
6% 6%
25%
611 611
9% 9%
75%
- Selling and Administrative Expenses 362 362
13% 13%
45%
- Research and Development Expense 131 131
23% 23%
16%
115 115
12% 12%
14%
- Depreciation and Amortization 48 48
36% 36%
6%
EBIT (Operating Income) EBIT 67 67
18% 18%
8%
Net Profit 30 30
85% 85%
4%

In millions SEK.

Don't miss a Thing! We will send you all news about Xvivo Perfusion directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Xvivo Perfusion AB is a medical technology company. The company is headquartered in Moelndal, Vastra Gotalands and currently employs 193 full-time employees. The company went IPO on 2012-10-08. The firm operates in two segments: Durable goods and Non-Durable goods. The Durable goods segment comprises sale and rental income from XVIVO Perfusion System (XPS) machines. The Non-Durable goods segment implies revenue from the sale of products and services that are solutions and disposable items. The Company’s product portfolio consists of Perfadex, STEEN Solution, XPS, XPS Disposable Kit, XVIVO Lung Cannula Set, XVIVO Organ Chamber, XPS PGM Disposable Sensors and Silicone Tubing Set. The firm markets its products in Europe, Asia, Middle East, and North & South America.

Head office Sweden
CEO Mr. Rosenblad
Employees 193
Website www.xvivogroup.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today